The UK company F2G Ltd. has announced a strategic collaboration with Japanese pharmaceutical company Shionogi & Co. Ltd. to develop and commercialize olorofim, an antifungal treatment for invasive fungal infections, in Europe and Asia.
The deal centers on olorofim, F2G’s oral antifungal therapy for the treatment of invasive aspergillosis, an infection that can be deadly for people with weakened immune systems. A spokesperson for F2G told us the collaboration covers China, Japan, Australia, and other major markets.
Under the terms of the agreement, Shionogi will conduct the clinical trials and subsequent registration and commercialization of olorofim for invasive aspergillosis in Europe and Asia. Shionogi will make an upfront payment to F2G of $100M and share development costs in global studies. F2G will also be eligible to receive additional regulatory and commercial milestones of up to $380M, as well as double-digit royalties on net sales.
“By joining forces with Shionogi, F2G will be able to progress the development of olorofim with a partner that has a proven track record in global drug and business development,” F2G’s spokesperson said.
The post F2G enlists Shionogi to bring antifungal treatment to Europe and Asia appeared first on Labiotech.eu.
© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.